Oncology CME

  • FEATURED

    BoardVitals Hematology and Oncology CME Board Review

    The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 CreditsTM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

    The BoardVitals Hematology and Oncology CME Review also features:

    • Quick and Convenient CME
    • Computer, phone, and tablet access
    • Constantly updated up-to-date questions
    • Questions that are targeted specifically to the exam
    • Online CME tracker
    • 100% Pass Guarantee
    • Statistical comparison to other Hematology and Oncology test-takers (Nationally)

     

    After completing this activity, you should be able to:

    • Make a diagnosis
    • Order and interpret results
    • Assess risk, determine prognosis, and apply principles from epidemiologic studies
    • Describe the underlying pathophysiology of disease and basic science knowledge

     

    Target Audience: Hematologists and Oncologists

    See full details chevron_right
    • Cost: $599
    • Credit hours: 27
    • CME credits awarded by: BoardVitals
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • SAVE $100 WITH CODE LEARN

    AudioDigest CME Oncology Platinum Membership

    The AudioDigest CME + CE + MOC Oncology Platinum Membership is our most comprehensive plan available. Get unlimited access to every lecture in our library across all specialties, including over 4,000 evidence-based audio lessons and written summaries with suggested readings and test questions certified for CME, CE, and MOC credits across 15 specialties.

    See full details chevron_right
    • Cost: $999
    • Credit hours: 4,300+
    • CME credits awarded by: Accreditation Council for Continuing Medical Education
    • Format: Audio
  • Lippincott ClinicalPulse Oncology

    Listen and learn the latest in Oncology on the go with Lippincott ClinicalPulse, the leader in medical publishing. This collection includes research outcomes and innovations from NEJM Journal Watch on topics such as anticancer therapeutics, breast cancer, and ethics just to name a few.

    See full details chevron_right
    • Cost: $495
    • Credit hours: 200+
    • CME credits awarded by: Accreditation Council for Continuing Medical Education; American Nurses Credentialing Center's Commission on Accreditation
    • Format: Online Audio, Mobile App Audio
  • FREE

    ScientiaCME Best practice in the systemic treatment of advanced and recurrent endometrial cancer

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Endometrial cancer is the most common gynecologic cancer and the fourth most common cancer in women living in the United States, with approximately 66,000 cancers of the uterine corpus diagnosed every year and over 12,000 associated deaths. The vast majority of women are diagnosed with endometrial cancer after the age of 50, and risk factors are obesity, level of physical activity, increasing age, and the presence of a variety of comorbid, chronic health conditions. The costs associated with endometrial cancer may amount to tens of thousands of dollars per patient, depending on the stage of disease upon diagnosis. The five-year survival rate for patients with localized disease is 95%, but survival rates drop to 18% in patients with advanced disease, one in ten patients is diagnosed with distant cancer, representing an area of ongoing clinical need.

    Target Audience:
    HCPs including: medical, including gynecologic, oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with advanced or recurrent endometrial cancer.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: August 25, 2023
    • Expiration of CME credit: August 25, 2024
  • FREE

    ScientiaCME Challenges and updates in the management of von Hippel-Lindau disease and related tumors

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Von Hippel-Lindau (VHL) disease is a rare genetic condition caused by an autosomal dominant mutation of the VHL tumor suppressor gene. The mutation gives rise to an abnormal VHL protein that cannot bind effectively to protein HIF-1α, leading to the transcription of multiple genes and upregulation of growth factors. The condition is thought to affect between 1 in 39,000 and 1 in 91,000, with a birth incidence of between 1 in 36,000 and 1 in 45,500. Diagnosis of VHL disease is established when the patient undergoes genetic testing and a pathogenic mutation of the VHL gene is found. Genetic testing is typically conducted if the patient has a family history of VHL or they are showing signs of VHL-related symptoms. VHL disease is characterized by tumors and cysts growing in various parts of the body, including the brain, spine, eyes, inner ears, pancreas, kidneys, adrenal glands, and reproductive tract. The clinical presentation of the disease is different in every patient and is impossible to predict, so close monitoring is required. Complications of the disease are on a case-by-case basis, but patients with VHL are at an increased risk of developing some cancers, particularly clear cell renal cell carcinoma (RCC) and pancreatic cancer.

    Target Audience:
    HCPs including: Medical and genitourinary oncologists, urologists, and nephrologists; physician assistants, nurse practitioners, and pharmacists specializing in the aforementioned areas of specialty; and any other HCPs involved or interested in treatment of VHL disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 08, 2023
    • Expiration of CME credit: September 08, 2024
  • FREE

    Myeloma bone disease: Monitoring and management

    In this online, self-learning activity:

    Multiple myeloma (MM) is the most common hematologic malignancy after non-Hodgkin lymphoma, with an incidence of over 34,000 and an annual mortality rate of over 12,000. MM-induced osteocyte apoptosis facilitates MM cell survival, and patients with MM are at high risk for bone disease. Osteolytic lesions are reported in up to four out of five newly diagnosed with MM, and throughout their disease course, up to 90% of patients will eventually develop bone lesions. The presence of bone lesions increases MM patient risk for skeletal-related events (SREs), such as fractures, spinal cord compression, or need for surgery or radiotherapy. Bone disease and SREs can have serious consequences in MM, leading to worsened quality-of-life and prospects for survival. Patients who experience fracture after MM diagnosis have a two-fold increased risk of death relative to those who do not experience fracture. Yet bone disease frequently goes untreated in patients with MM, suggesting that clinicians are not familiar with the serious effects of MM.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Expiration of CME credit: 12/21/2024
  • FREE

    Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Graft-versus-host disease (GvHD) is an immune-mediated response that occurs in recipients of allogenic hematopoietic cell transplantation (HCT). GvHD can be further categorized into acute and chronic cases. Maculopapular rash, follicular erythema, epidermolysis, are common manifestations of acute GvHD, in addition to liver and gastrointestinal dysfunction such as hyperbilirubinemia, nausea, and diarrhea. This activity focuses on chronic GvHD, which has more extensive multi-organ involvement including the liver, eyes, mouth, lungs, skin, genitalia, and gastrointestinal tract.

    Target Audience:

    The following HCPs: hematologists and oncologists; nurse practitioners, physician assistants, and pharmacists who specialize in oncology; and those who otherwise commonly care for or clinically encounter patients with GVHD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 03/31/2023
    • Expiration of CME credit: 03/31/2025
  • Oakstone MKSAP® 19 Audio Companion

    Expert Advice and Insightful Commentary

    The MKSAP® 19 Audio Companion sheds light on the latest diagnostic approaches, management strategies, and treatment guidelines. In this comprehensive audio CME program, you’ll join host Donald L. Deye, MD, FACP, as he leads lively discussions with esteemed colleagues in 11 internal medicine subspecialties. Listen as experienced clinicians from some of the world’s finest medical institutions share patient stories, insightful views of recent clinical advances, and more.

    Anytime, Anywhere Audio CME

    With the MKSAP 19 Audio Companion, you get:

    • All-new advice and commentary — a reliable, and entertaining way to learn current oncology trends, the latest approaches to diabetes treatment, COVID updates, new tactics for managing patients with COPD, and so much more
    • An easy way to prep for your ABIM certification or MOC exam
    • Flexible learning to fit your schedule — in your car, between appointments, while you work out
    • Companion booklets — high-impact PDF learning aids to quickly review and retain key points (print booklets available for an additional charge)
    • The opportunity to earn AMA PRA Category 1 Credits and ABIM MOC points
    • Four FREE sets of extension questions — a $350 value that brings you incremental AMA PRA Category 1 Credits™ and MOC points

    Audience

    General internists and primary care physicians; subspecialists who need to remain up to date in internal medicine; residents preparing for the certifying examination in internal medicine; physicians preparing for the recertification examination. 

    Learning Objectives

    • Discuss the most clinically relevant patient care information in all subspecialties of Internal Medicine based on the medical literature of the last 3 to 5 years
    • Describe clinical situations in which this new knowledge will improve quality of care
    • Diagnose disease states that are less common and sometimes overlooked and confusing
    • Determine when to refer patients for surgery or care by subspecialists
    See full details chevron_right
    • Cost: $1297
    • CME credits awarded by: Oakstone Publishing, LLC
    • Format: On-Demand Online, Online Audio, Audio CD
    • Material last updated: Part A Release: August 31, 2021 Part B Release: January 31, 2022
    • Expiration of CME credit: Expiration Date: August 31, 2024 Expiration Date: December 31, 2024
  • StatPearls Unlimited Physician MD/DO/PA CME

    Stay on top of your game with the StatPearls Physician Unlimited CME programs. With 6,046 activities, StatPearls is the largest CME provider in the world. These Pub-Med Indexed articles are categorized into 162 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

    Pricing Options

    • 6 Month subscription: All 6,339 CME Activities $249 per 6 months
    • Annual subscription: All 6,339 CME Activities $349 per 1 year
    • Lifetime: All 6,339 CME Activities + Access to Board Reviews Forever $1999
    See full details chevron_right
    • Cost: Varies
    • CME credits awarded by: ETSU
    • Format: On Demand Online & Board Reviews
  • Oakstone CME Molecular Diagnostics: Cancer Diagnosis and Patient Management

    Learn Now: Advances in Molecular Diagnostics

    In Molecular Diagnostics: Cancer Diagnosis and Patient Management, experts in the field review current concepts and up-to-date techniques, delving into the appropriate use of molecular assays for different tumor types to inform diagnosis, prognosis, or treatment using evidence-based guidelines.

    Lectures in this online CME course illustrate common diagnostic pitfalls, with additional focus on variant interpretation and the complexity of billing for molecular tests. It’s continuing medical education that will help you to:

    • Develop appropriate tissue-handling protocols
    • Evaluate cytogenetic and molecular techniques, including next generation sequencing assays
    • Recognize cost-effective, time-sensitive approaches to molecular studies, including cell free DNA testing
    • Determine the process of clinical interpretation of genetic variation
    • Analyze costs and potential sources of revenue for molecular diagnostics programs
    • Consider essential and emerging biomarkers in common adult and pediatric solid and liquid tumors
    See full details chevron_right
    • Cost: $895
    • Credit hours: 18
    • CME credits awarded by: Oakstone Publishing, LLC.
    • Material last updated: October 30, 2021
    • Expiration of CME credit: January 31, 2024